Bryan Johnson· Author
Almost 4 years ago the Intervention Testing Program ITP revealed that Canagliflozin, an SGLT-2 inhibitor approved for the treatment of type-2 diabetes, produced significant lifespan increase in heterozygous mice.
Loading…
The evidence is convergent. Multiple independent sources reach the same conclusion, the underlying mechanism is well-characterized, and even the field's most cautious voices treat it as worth doing.
Almost 4 years ago the Intervention Testing Program ITP revealed that Canagliflozin, an SGLT-2 inhibitor approved for the treatment of type-2 diabetes, produced significant lifespan increase in heterozygous mice.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
A recent study in Nature Aging has attributed the lifespan extension effect of SGLT-2 inhibition by Canagliflozin to the increased removal of senescent cells.
sglt2 Inhibitors will definitely come back to because they're super interesting uh I think that can agaflows and its derivatives are very promising drugs in the Jiro protective space